GlassScriptPhysician profile
Kenneth S Haft
NPI 1972529717
$7,446.48
in general payments reported to CMS, 2019-2025
31 companies · $493 in 2025
The $493 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $923 · 2021: $1,393 · 2022: $303 · 2023: $343 · 2024: $3,806 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,522 · Food and Beverage: $1,113 · Travel and Lodging: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,521.72 |
| Food and Beverage | $1,113.49 |
| Travel and Lodging | $1,006.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,575.25 | 2024 | |
| Paratek Pharmaceuticals, INC. | $1,185.89 | 2021 | |
| Actelion Pharmaceuticals, LTD | $669.24 | 2020 | |
| Glaxosmithkline, LLC. | $434.24 | 2019-2025 | Trelegy Ellipta, Nucala |
| Amgen INC. | $220.12 | 2022-2025 | Tezspire, Tavneos |
| Astrazeneca Pharmaceuticals LP | $201.01 | 2019-2025 | Breztri, Airsupra |
| Insmed, INC. | $139.05 | 2019-2024 | Arikayce |
| Genzyme Corporation | $134.22 | 2021-2025 | |
| Grifols USA, LLC | $116.13 | 2020-2025 | Prolastin-C Liquid |
| Vifor Pharma, INC. | $93.32 | 2024-2025 | Zemaira |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.61 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $78.94 | 2021-2024 | Acthar |
| Genentech USA, INC. | $75.96 | 2021-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $42.42 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $41.84 | 2023 | Uptravi, Opsumit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $38.06 | 2019 | |
| Pfizer INC. | $37.23 | 2024-2025 | |
| Philips North America LLC | $30.50 | 2020-2022 | |
| Mylan Specialty L.P. | $26.31 | 2020-2022 | |
| Covidien LP | $25.77 | 2019-2020 | |
| Atricure, INC. | $25.58 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Ani Pharmaceuticals, INC. | $25.20 | 2023 | Purified Cortrophin Gel |
| Blueprint Medicines Corporation | $19.18 | 2023 | Ayvakit |
| Tactile Systems Technology INC | $18.94 | 2023 | Flexitouch Plus, Entre Plus |
| Gilead Sciences, INC. | $17.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.68 | 2022 | |
| Lilly USA, LLC | $15.40 | 2025 | Zepbound |
| United Therapeutics Corporation | $13.64 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.08 | 2020 | |
| Merck Sharp & Dohme LLC | $12.67 | 2019 | |
| Sandoz INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Haft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.